Drugs / EV
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05845814 Background | Jun 2023 → May 2027 expected | urothelial carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05845814 ↗ |
| Route | Intravenous | “EV at 1.25 mg/kg, administered as an IV infusion” NCT05845814 ↗ |